Atara Biotherapeutics, Inc. (ATRA)
9.76
+0.23
(+2.41%)
USD |
NASDAQ |
Sep 04, 16:00
10.34
+0.58
(+5.94%)
After-Hours: 20:00
Atara Biotherapeutics Shareholders Equity (Quarterly) : -37.00M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -37.00M |
| March 31, 2026 | -37.31M |
| December 31, 2025 | -38.50M |
| September 30, 2025 | -36.63M |
| June 30, 2025 | -35.04M |
| March 31, 2025 | -55.07M |
| December 31, 2024 | -97.28M |
| September 30, 2024 | -90.54M |
| June 30, 2024 | -110.87M |
| March 31, 2024 | -98.31M |
| December 31, 2023 | -99.23M |
| September 30, 2023 | -50.84M |
| June 30, 2023 | 7.454M |
| March 31, 2023 | 64.96M |
| December 31, 2022 | 126.64M |
| September 30, 2022 | 187.11M |
| June 30, 2022 | 257.48M |
| March 31, 2022 | 224.32M |
| December 31, 2021 | 279.61M |
| September 30, 2021 | 310.14M |
| June 30, 2021 | 331.54M |
| March 31, 2021 | 399.04M |
| December 31, 2020 | 462.34M |
| September 30, 2020 | 353.94M |
| June 30, 2020 | 381.12M |
| Date | Value |
|---|---|
| March 31, 2020 | 252.82M |
| December 31, 2019 | 290.78M |
| September 30, 2019 | 318.44M |
| June 30, 2019 | 232.28M |
| March 31, 2019 | 283.93M |
| December 31, 2018 | 338.86M |
| September 30, 2018 | 403.05M |
| June 30, 2018 | 452.50M |
| March 31, 2018 | 439.18M |
| December 31, 2017 | 177.86M |
| September 30, 2017 | 205.96M |
| June 30, 2017 | 221.14M |
| March 31, 2017 | 233.13M |
| December 31, 2016 | 253.74M |
| September 30, 2016 | 270.20M |
| June 30, 2016 | 290.24M |
| March 31, 2016 | 303.83M |
| December 31, 2015 | 315.10M |
| September 30, 2015 | 333.75M |
| June 30, 2015 | 149.26M |
| March 31, 2015 | 166.09M |
| December 31, 2014 | 103.18M |
| September 30, 2014 | 51.54M |
| June 30, 2014 | 56.22M |
| March 31, 2014 | 60.17M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 21.02M |
| Total Liabilities (Quarterly) | 58.02M |
| Debt to Equity Ratio | -1.390 |
| Current Ratio | 1.976 |
| Net Debt Paydown Yield | 5.36% |